Vaccines For Blocking Transmission of Plasmodium vivax
Posted Feb 27 2011 7:00pm
Description of Invention: This invention relates to novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
For Licensing Information Please Contact: Admin. Licensing Spec-InfectDis NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: anos@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220
Description of Invention:
This invention relates to novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
Inventors:
David C Kaslow (NIAID)
Portfolios:
Infectious Diseases
Infectious Diseases - Vaccines
For Licensing Information Please Contact:
Admin. Licensing Spec-InfectDis
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: anos@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220
Ref No: 1182
Updated: 02/2011